Drug intelligence / Profile preview

DA-2811-R

Development stage: Phase 1
Lead developer: Dong-A ST
Modality: Small Molecules
Administration: Oral

Overview

DA-2811-R, also known as Dapagliflozin formate (DA-2811), is an ester prodrug of dapagliflozin developed by Dong-A ST Co., Ltd.. It was designed to enhance the stability and pharmaceutical manufacturing process of dapagliflozin. Upon absorption, DA-2811-R rapidly converts into its active form, dapagliflozin, which is a small molecule sodium-glucose cotransporter-2 (SGLT2) inhibitor primarily indicated for the treatment of Type 2 Diabetes Mellitus. Dapagliflozin itself is also used to reduce the risk of hospitalization for heart failure and worsening kidney disease in certain adult populations.

Other names: Dapagliflozin formate

Targets

SGLT2 (Sodium-glucose cotransporter protein subunit 2)

Beyond the preview

Go deeper on DA-2811-R.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DA-2811-R.

Explore the full profile